Myocarditis associated with *Plasmodium vivax* malaria: a case report

Ana Maria Revoredo da Silva Ventura[^1],[^2], Tânia do Socorro Souza Chaves[^1], Julius Caesar Mendes Monteiro[^3], Carina Guilhon Sequeira[^2], Maria Deise de Oliveira Ohnishi[^2], Rosana Maria Feio Libonati[^4], Rita Catarina Medeiros Sousa[^4],[^5] and Jose Maria de Souza[^1]


ABSTRACT

Malaria remains a major public health problem in Brazil where *Plasmodium vivax* is the predominant species, responsible for 82% of registered cases in 2013. Though benign, *P. vivax* infection may sometimes evolve with complications and a fatal outcome. Here, we report a severe case of *P. vivax* malaria in a 35-year-old Brazilian man from a malaria endemic area, who presented with reversible myocarditis.

Keywords: Malaria. Reversible myocarditis. Severe *Plasmodium vivax* malaria.

Case Report

The 35-year-old male patient was an electrician and 5-year resident of Anajás, State of Pará, Brazil. He had no previous history of malaria or cardiovascular system disorders.

After discharge from the hospital following spinal cord injury due to an occupational accident, the patient presented with a 5-day history of fever, chills, headache, and asthenia, and was again hospitalized. In the hospital, a thick blood smear was positive to *P. vivax* (30,000 asexual parasite forms/mm³), and he was treated with 150mg chloroquine (4 tablets on the first day and 3 tablets on the second and third days) plus 15mg primaquine (2 tablets/day for 7 days) according to the treatment regime proposed by the Health Ministry of Brazil[^4].

In the third day of hospitalization, primaquine was discontinued and the patient transferred to the intensive care unit due to worsening respiratory distress concomitant with signs of heart failure and petechial hemorrhagic suffusion on the thorax, abdomen and lower limbs (Figure 1). Normal white blood cell count observed at admission evolved to leukopenia (3,000/µL/mm³), and hemoglobin decreased from 12.8g/dL to 8.9g/dL. Thrombocytopenia was present both at admission (20,000 platelets/mm³) and in day 3 (15,000 platelets/mm³).

Chest radiography revealed pulmonary edema and cardiomegaly (Figures 2A and 2B), Ecocardiography revealed left ventricular dilatation during systole (5mm, normal = 4mm) and diastole (73mm, normal = 56mm), decreased left ventricular ejection fraction (LVEF) (47%, normal > 58%), diffuse hypokinesia and mild mitral regurgitation (Figure 3). Blood and urine cultures were negative. Results of serological tests for dengue, yellow fever, infectious mononucleosis, Chagas disease, enterovirus (Coxsackie and Echovirus), human immunodeficiency virus (HIV) and human T-lymphotropic virus (HTLV) were also negative. Polymerase chain reaction (PCR) to confirm *P. vivax* infection was not performed.

The patient gradually improved with antibiotic therapy (oxacillin and ceftriaxone), administered with antimalarials due to the clinical severe condition. He was also administered diuretics (furosemide and spironolactone), digoxin and...
carvedilol and was maintained in negative fluid balance. A thick blood smear was negative to \textit{Plasmodium} sp to day 5, and after 12 days of treatment, he was discharged (February, 11th, 2009) in regular health and administered carvedilol (1 tablet, 2 times/day).

Thereafter, he did not return to Anajás and was monitored on a monthly basis in the Laboratory of Clinical Malaria Essay at the Evandro Chagas Institute, in Ananindeua, State of Pará, Brazil, relapsing on the 46th day post-treatment, with 3,500 asexual \textit{P. vivax} parasite forms/mm³. At this time, the standard treatment was reintroduced. A negative blood smear was observed on day 4, which persisted for up to 90 days with monthly controls. In May - 2009, radiography showed normal lung transparency and normal cardiac area; electrocardiography showed normal sinus rhythm; and echocardiography showed a 34-mm ventricular diameter in systole, 50-mm left ventricular diameter in diastole, LVEF of 60%, and heart valves without morphologic or dynamic abnormalities.

The worldwide prevalence of severe \textit{P. vivax} malaria cases is not well known, probably because there are no defined severity criteria for malaria caused by \textit{P. vivax}. However, the World Health Organization (WHO) criteria for severe \textit{P. falciparum} malaria seem to apply to the broad spectrum of the most severe \textit{P. vivax} malaria cases described.

\textbf{DISCUSSION}

A \textit{Plasmodium vivax} malaria case complicated with myocardial failure and hemorrhagic diathesis in an adult man from a malaria endemic area (Anajás) in the Amazon region (Brazil) without a previous history of malaria, was reported in addition to the first \textit{P. vivax} malaria episode in six patients who presented with cardiac involvement (from a series of 22 malaria cases admitted in a German hospital). Similarly a case of myocarditis associated with primary \textit{P. vivax} malaria has been reported in a woman from South Korea. Though these primary cases were related to the absence of specific immunity to the parasite, severe cases, including cardiac damage, may occur in patients with previous malaria who have some degree
FIGURE 3 - Echocardiography showing left ventricular dilatation in systole and diastole and mild mitral regurgitation in a patient with Plasmodium vivax malaria.

of immunity, making this relationship between myocarditis and malaria unclear.

Our patient presented with high parasitemia (30,000 asexual parasite forms/mm³), which might have influenced the severity, although additional studies are necessary to determine to what extent high parasite density may be considered a marker of severity in Plasmodium vivax infections, as indicated by Lacerda et al.6.

In a recent review of cardiac involvement in parasitic infection, Hidron et al. reported that Trypanosoma cruzi is the main parasite to compromise the heart; however the authors did not mention malaria. Myocardial involvement in malaria seems uncommon, with unclear physiopathology in the majority of cases associated with Plasmodium falciparum. Autopsy findings have shown parasites and parasitized red blood cells blocking myocardial capillaries, leading to ischemic cardiomyopathy, and a dilated heart has also been observed. In addition, the toxic effects of high levels of tumor necrosis factor (TNF) may play a role in the inflammatory process in the heart, with migration of lymphocytes and plasma cells, among others.8,9

Besides cardiac involvement, the present patient manifested signs of septic shock. Myocardial dysfunction is one of the diagnostic criteria for severe sepsis and septic shock and frequently accompanies these conditions, presenting as ventricular dilatation and reduced ejection fraction; when properly managed, it is reversible. An infection stimulus, generally an endotoxin or another microbiological element (e.g., malaria endotoxins), induces the release of local and systemic inflammatory mediators, especially alpha-TNF and interleukin (IL)-1β, from monocytes/macrophages and other cells. These cytokines stimulate polymorphonuclear leukocytes, macrophages, and endothelial cells to release a number of downstream inflammatory mediators, including platelet activating factor and nitric oxide, further amplifying the inflammatory response. Several anti-inflammatory mediators, such as IL-10, transforming growth factor-beta, and IL-1 receptor antagonist, are also released as part of this amplification cascade.

The myocardial involvement in the present patient was probably caused by the parasite itself and/or due to an inflammatory-trigged response; the physiopathology of the events
that occur in \textit{P. vivax} and \textit{P. falciparum} infections reflects the immune response (mainly an unbalance of pro and anti-inflammatory cytokines) of the host towards the parasite, which is usually more prominent in the first \textit{Plasmodium} infection\textsuperscript{10}, as was observed in this case. Other infections responsible for compromised myocardial function were ruled out: blood and urine cultures, dengue, yellow fever, infectious mononucleosis, Chagas disease, enterovirus (Coxsackie and Echovirus), HIV and HTLV serology were negative.

Though chloroquine can cause cardiomyopathy, particularly with long-term use\textsuperscript{11}, the clinical manifestation of heart involvement, including tachycardia, dyspnea, and fatigue with minimal exertion, in this patient were present before \textit{P. vivax} diagnosis and administration of chloroquine.

Despite a lack of \textit{P. vivax} confirmation or \textit{P. falciparum} exclusion by PCR, the following three aspects of the present case strongly suggest \textit{P. vivax} etiology: a) several thick blood slides were positive to \textit{P. vivax} during hospitalization, determined by an expert microscopist, from a reference Malaria Diagnosis Center, and there was a prompt response to chloroquine with a decrease in and clearance of parasitemia; b) in Brazil, strains of \textit{P. falciparum} are usually resistant to chloroquine\textsuperscript{12}; and c) the relapse during the follow up, which was expected to a certain extent because primaquine was discontinued due patient’s worse clinical condition, included lung involvement, heart failure, petechial hemorrhagic suffusion, and thrombocytopenia.

This case report demonstrates that \textit{P. vivax} infection can evolve with severe complications and poor outcomes. Though uncommon, myocarditis can occur with \textit{P. vivax} malaria and health professionals should be aware of this possibility for appropriate monitoring and management.

\textbf{REFERENCES}